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Brain tumours including the most common form of glioblastomas
continue to be important neoplasia in the world affecting a large
number of individuals. Recent molecular studies indicate that acti-
vation of proto-oncogenes, growth factors and receptors such as
the epidermal growth factor receptor (EGFR) was an important
event in glioblastomas (Libermann et al, 1985; Nagane et al, 1996;
Louis, 1997; Ng and Lam, 1998). EGFR is found to be over-
expressed in up to 50% of all reported cases of glioblastomas
(Libermann et al, 1985; Wong et al, 1987; Schober et al, 1995).
Genetic abnormalities such as gene rearrangement and amplifica-
tion are detected in the late stages of gliomas, suggesting an
important role played by EGFR in tumour proliferation and malig-
nant transformation (Wong et al, 1987). EGFR is a transmembrane
glycoprotein of 170 kDa and is composed of an extracellular
ligand-binding domain, a single hydrophobic membrane-spanning
domain and a cytoplasmic tyrosine kinase domain (Yarden and
Ullrich, 1988). Binding of EGF or transforming growth factor-
alpha (TGF-a) to EGFR results in receptor dimerization,
autophosphorylation of receptor itself and phosphorylation of
cellular substrates leading to cell division. The use of antisense
RNA or cDNA of EGFR in transfecting tumour cells in order to
block the function of enhanced EGFR has been reported pre-
viously (Moroni et al, 1992; Chakrabarty et al, 1995; Liu et al,
1995; Wang et al, 1995; Giovanni et al, 1996). However, the
effects of antisense-EGFR on the cell cycle-regulated proteins,
especially those associated with the nuclear-processing events, are
still unclear.
Moreover, inactivation of tumour suppressor genes has also
been documented for the pathogenesis of many neoplastic diseases
including the glioblastomas (Louis, 1997). The tumour suppressor
p53 is known to play a role in the development of many types of
cancers (Smith and Fornace, 1995; Sidransky and Hollstein,
1996), and it is one of the highly mutated genes reported in the
literature so far. It plays a pivotal role in cellular response to DNA
damage by activating genes for DNA repair, apoptosis, G1 cell
cycle arrest and suppression of cell growth (Canman et al, 1994).
On the other hand, the PML gene (for promyelocytic leukaemia)
encodes a growth and transformation suppressor, and has been
identified at the non-random chromosomal translocation break
point of acute promyelocytic leukaemia (APL) (Chang et al, 1995;
Lamond and Earnshaw, 1998). PML is a nuclear phosphoprotein
that has been shown to inhibit cell growth and the transformed
phenotypes of tumour cells (Mu et al, 1994; Chang et al, 1995; Liu
et al, 1995) and is localized in nuclear bodies (NB) or PML onco-
genic domain (POD) (Koken et al, 1995). Moreover, PML is
involved in cell cycle arrest and viral replication (Everett and
Maul, 1994; Pivion et al, 1995), and significant increase in PML
nuclear bodies and a non-aggregated soluble form were found in
cells progress through G1 and S phase of the cell cycle (Terris et
al, 1995).
We have recently reported on the use of antisense-EGFR trans-
fection to inhibit the proliferation and to induce the differentiation
of glioblastoma cells (Tian et al, 1998). We have also documented
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the cell cycle regulation of DNA damage-induced expression of
the suppressor PML, and that p53 may regulate the expression of
PML (Chan et al, 1997). Moreover, altered expression of PML in
hepatocellular carcinomas was also identified (Chan et al, 1998).
To determine if the nuclear processing events may be involved in
the membrane signal-transduction pathway of EGFR, we analysed
the expression of several cell cycle-regulated proteins, including
p53 and PML, in human glioblastoma cells treated with the anti-
sense-EGFR.
MATERIALS AND METHODS
Construction of antisense-EGFR vector
The construction of the antisense-EGFR and the cloning of the
transfected cells have been described previously (Tian et al, 1998).
The EGFR cDNA fragment (BamHI-BamHI) derived from PE7
was inserted in reverse orientation at the BamHI site of the pBabe-
puro vector (Morgenstern and Land, 1990; Liu et al, 1995). This
cDNA corresponds to the last 256 amino acid residues of the
extracellular domain, the entire transmembrane domain and the
first 61 amino acid residues of the cytoplasmic domain of EGFR.
Cell culture and transfection
The human glioblastoma cell line U87MG (American Type
Culture Collection, Rockville, MD, USA) was grown in minimum
essential medium-alpha (MEM-a) medium (Gibco, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum (FBS),
100 mg ml–1 streptomycin and 100 U ml–1 penicillin, in a humidi-
fied atmosphere of 5% carbon dioxide at 37°C. Cells were trans-
fected with the antisense-EGFR constructs using the Transfectam
reagent (Promega Corp., Madison, WI, USA). Stable clones (AS-1
and AS-2) were selected in 1 mg ml–1 puromycin (Sigma Chemical
Co., St Louis, MO, USA) as described previously (Tian et al,
1998).
The effect of EGF was determined by incubating cells with
media with low concentration of FBS (1%). Approximately
1 ´ 104 glioma cells were incubated in MEM-a supplemented
with 10% FBS for 24 h at 37°C. Cells were then treated with
100 ng ml–1 of EGF in MEM-a +1% FBS. The viability of the
cells was determined by the trypan blue dye exclusion method, and
all the experiments of cell growth were performed in triplicates
each for three times.
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Figure 1 Flow cytometry analysis of glioblastoma cells transfected with the antisense-EGFR. U87MG cells were transfected with the vector alone or with the
antisense-EGFR constructs as described in Methods. The stable clones were isolated and analysed by flow cytometry for different phases of the cell cycle996 XX Tian et al
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Flow cytometry analysis of DNA ploidy
The method for measuring the proportions of cells in the various
cell cycle phases was performed with a Coulter Epics XL flow
analyser (Coulter Corp., FL, USA) as described previously (Tian
et al, 1998). In brief, cells were fixed in ethanol, stained with
50 mg ml–1 propidium iodide (Sigma) containing 0.1% Triton
X-100 and 1% RNAase, and analysed by the flow analyser. The
percentages of cells in different phases of the cell cycle were
analysed by the Multicycle DNA Cell Cycle program (Phoenix
Laboratories, San Diego, CA, USA).
Immunohistochemical staining
Immunohistochemical staining was performed with the following
antibodies: affinity-purified rabbit antibody raised against the
recombinant PML protein (Chan et al, 1997), rabbit anti-human
EGFR antibody (Sc-03, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), rabbit anti-human cyclin-dependent kinase
4 (cdk4) (Sc-601, Santa Cruz Inc.), mouse anti-human Rb
(14001A, PharMingen, San Diego, CA, USA), mouse anti-human
p16 (13251A, PharMingen), mouse anti-human p21H-ras (M637,
DAKO A/S, Copenhagen, Denmark), or p53 (DO7, Novocastra
Lab., Newcastle upon Tyne, UK). Cells were cultured on cover-
slip, and fixed in cold methanol. The slides were boiled in 10 mM
sodium citrate buffer (pH 6.8) for 10 min in a microwave oven.
After treatment with 3% hydrogen peroxide in methanol, the
samples were blocked with the blocking solution (5% bovine
serum albumin (BSA) in phosphate-buffered saline (PBS)), and
then incubated with the first antibodies against: PML (1:2000),
EGFR (1:50), cdk4 (1:25), retinoblastoma (Rb) (1:50), p16 (1:25),
p53 (1:50) or H-ras (1:25), for 2 h at room temperature. After
washing, the samples were incubated for 30 min with the
secondary antibodies, and were visualized by the peroxidase anti-
peroxidase method or avidin biotin–peroxidase complex method.
After counterstaining weakly with haematoxylin and briefly
washing with 30 mM ammonium hydroxide, the slides were
mounted. All of the immunostaining was repeated at least twice.
RESULTS
Decrease in S phase fraction of glioblastoma cells with
antisense-EGFR
The antisense-EGFR constructs were transfected into a glioblast-
oma cell line U87MG and stable transfected clones were isolated.
Flow cytometry analysis of the stable antisense-EGFR clones in
U87MG cells indicated that the parental cell U87MG contained
62.5% G1 cells while the G2/M was 7.7%, and S phase cells was
29.9% as shown in Figure 1A. Similar ratio was obtained in
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Figure 2 Effect of EGF on glioblastoma cells transfected with the antisense-EGFR. U87G cells, cells transfected with the empty vector pBabe-puro or the
antisense-EGFR constructs were resuspended in media containing low level of FBS (1%). EGF was added to the cells at 0.1 mg ml–1, and the rate of cell growth
was determined at various time intervals. (A) Parental cells; (B) cells treated with empty vector; (C and D) antisense-EGFR clones AS-1 and AS-2 respectively.
The symbol (s) represents cells treated with EGF, while the symbol (u) represents untreated cellsAltered PML and p53 in antisense-EGFR glioblastoma 997
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Figure 3 Altered expression of EGFR, PML, p53 and cdk4 in glioblastoma cells transfected with the antisense-EGFR constructs. The parental cells U87MG
(column 1) and cells with the empty vector pBabe-puro (column 2) or with the antisense-EGFR (AS-1 and AS-2) in columns 3 and 4 respectively were
immunohistochemically stained with antibodies against EGFR (row A), PML (row B), p53 (row C), and Cdk-4 (row D) respectively as described in Methods. The
samples stained with PML in row B were not counter-stained and the original magnification for all of the prints was 200´998 XX Tian et al
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U87MG cells transfected with the vector pBabe-puro alone
(U87MG/pBabe) (Figure 1B). However, in cells transfected with
the antisense-EGFR constructs, the fraction of G1 cells increased
to 82.9% and 80.2% in two separate clones, AS-1 (Figure 1C) and
AS-2 (Figure 1D) respectively. The ratio of G2/M cells did not
change much, at approximately 6.6–7.5%, but the S phase cells
decreased to 10.5% and 12.3% respectively for AS-1 and AS-2
cells. The experiment was repeated three times and similar results
were obtained.
Effect of EGF on glioblastoma cells with
antisense-EGFR
To determine if the transfected cells would still respond to the
proliferative effect of EGF, cells were resuspended in media with
low level of FBS (1%), and EGF was added to the media of
different cell clones. The growth rates of these cells were then
monitored. As shown in Figure 2A and 2B for the control parental
U87MG cells and the cells with the empty vector pBabe-puro
respectively, the cells responded positively to the growth-stimula-
tion of EGF. In contrast, the clones treated with antisense-EGFR
(AS-1 and AS-2 for Figure 2C and 2D respectively), did not
respond well to the exogenously added EGF indicating that the
antisense-EGFR abrogated the ability of the cells to respond to
EGF. At 7 days post-treatment with EGF, the cell numbers for the
parental and the empty vector were 14.1 and 16.2 (´ 104) respec-
tively, while the numbers for the two antisense EGFR-clones,
AS-1 and AS-2, were 1.2 and 1.7 (´ 104) respectively.
Suppression of EGFR expression in glioblastoma cells
treated with antisense-EGFR
The effect of the antisense-EGFR on the expression of EGFR was
then determined. As shown in Figure 3 row A, the expression of
EGFR was analysed by immunohistochemical staining with an
antibody against EGFR. Strong staining of EGFR was found in the
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Figure 4 Expression of Rb, p16 and H-ras in glioblastoma cells transfected with the antisense-EGFR. U87MG cells, cells with the empty vector or antisense-
EGFR were immunohistochemically stained with a rabbit polyclonal antibody against the Rb (row A), p16 (row B) and H-ras (row C) respectively as described in
Methods. Column 1, parental U87MG cells; column 2, cells with the vector pBabe-puro; columns 3 and 4, antisense-EGFR clones AS-1 and AS-2 respectively.
The original magnification for all of the prints was 200´Altered PML and p53 in antisense-EGFR glioblastoma999
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parental U87MG cells and the vector-transfected cells
U87MG/pBabe. In contrast, weak or undetectable staining was
found in the antisense-EGFR cells AS-1 and AS-2 respectively.
There were significant decreases in EGFR expression in the
antisense-EGFR clones as compared to the controls. We have
previously shown by Western blotting (Tian et al, 1998) that the
EGFR protein in the two antisense clones (AS-1 and AS-2) were
undetectable. However, the control cells expressed a large amount
of EGFR protein. In addition, the parental U87MG and the vector
alone-transfected clone were large, round or spindle-shape cells
which are characteristics of transformed cells, while the antisense
clones AS-1 and AS-2 were small, elongated and bipolar in shape
with long processes, which are properties of differentiated glial
cells. Moreover, the parental and empty vector-transfected cells
had very low levels of expression of the differentiation marker
GFAP, while the AS-1 and AS-2 contained high GFAP protein
(Tian et al, 1998).
Altered expression of PML in glioblastoma cells with
the antisense-EGFR
We have previously published on the suppressor PMLbeing a cell
cycle-regulated gene (Chan et al, 1997) and that transfection of
PMLarrests cells in G1. In addition, the optimal expression of
PML is also at G1 (Mu et al, 1995). Thus, we were interested to
see whether the antisense-EGFR would alter the expression of cell
cycle-regulated genes such as the PML. Immunohistochemical
staining of PML was performed on control cells and cells treated
with antisense-EGFR. As shown in Figure 3 row B, PML expres-
sion in 80–90% of the parental cells and the vector-alone cells,
displayed a nuclear dot like pattern. The number of POD was
about 2–6 per cell and the average number of dots was 4 per cell.
Moreover, the intensity of dots in the majority of cells was
relatively weak. In contrast, increased PML labelling was found in
the antisense clones (AS-1 and AS-2 in Figure 3, panels B3 and B4
respectively). The intensity was strong and the number of nuclear
bodies increased to 10 or more. Around 60–70% of the antisense-
EGFR-treated cells showed a patched-like pattern or a homoge-
neous granulated pattern of strong PML staining, consistent with
data reported previously by us and by others in cell cycle-arrested
cells (Koken et al, 1995; Chan et al, 1997). These results indicate
that enhanced expression of PML and possibly a redistribution of
PML were found in antisense-EGFR cells as compared to the
control cells.
Enhanced expression of p53 in glioblastoma cells with
the antisense-EGFR
Since it is known that the tumour suppressor p53 plays a pivotal
role in inhibiting cell growth and in G1-cell cycle arrest, and that
p53 may regulate the expression of PML or vice versa, we were
interested to know if the expression of p53 was also altered in the
cells treated with antisense-EGFR. It was reported previously that
p53 in U87MG is wild-type (Gomez-Manzano et al, 1997). We
then determined the expression of p53 with an antibody against
p53 in these four different clones as shown in Figure 3, row C.
Immunohistochemical staining with an antibody against p53 
(DO-7) labelled a large number of the cells negative or weak
staining in the parental cells and the empty vector-transfected
cells as shown in Figure 3, Panels C1 and C2 respectively. In
contrast, the p53 staining of a considerable number of cells in the
antisense-EGFR clones, AS-1 and AS-2, was much stronger
(Figure 3, panels C3 and C4 respectively). Approximately 1000
cells were counted for each slide of three independent experi-
ments, and the percentage of cells with strong staining of p53 in
parental and empty vector were calculated to be 3% ±2 standard
deviation (s.d.) and 3% ±3 (s.d.), while the AS-1 and AS-2 cells
were 11% ±5 (s.d.) and 8% ±3 (s.d.) respectively. The proportion
of cells with intermediate levels of p53 staining were 18% ±4
(s.d.), 14% ±2 (s.d.), 54% ±3 (s.d.) and 50% ±7 (s.d.) for
parental, empty vector, AS-1 and AS-2 respectively. In contrast,
the proportions of cells stained negative or weak were 79% ±6
(s.d.), 83% ±4 (s.d.), 35% ±3 (s.d.) and 41% ±5 (s.d.) for
parental, empty-vector, AS-1 and AS-2 respectively. About three-
fold increase in the strong staining cells and intermediate staining
cells, and twofold decrease of cells stained weak or negative were
observed in the antisense-EGFR clones, which indicate that p53 is
involved in the EGFR pathway also.
Expression of cdk4, Rb, p16INK4A, and H-ras in
To determine if other cell cycle-regulated gene products were also
altered in the antisense-EGFR-transfected cells, cdk4 was stained
in control cells and antisense clones. As shown in Figure 3, row D,
the protein of cdk4 was mostly found in the nucleus of U87MG
and the U87MG/pBabe cells (Figure 3, panels D1 and D2 respec-
tively) similar to those of PML and p53. Unlike p53 and PML, the
staining of cdk4 in antisense-EGFR clones of AS-1 and AS-2
(Figure 3, panels D3 and D4 respectively) were similar to the
controls.
Similarly, we have examined the expression of another tumour
suppressor and cell cycle regulator, the retinoblastoma gene (Rb)
in these cells. As shown in Figure 4, row A, the expression of Rb
was analysed by immunohistochemical staining with an anti-Rb
antibody. Rb staining was found to be quite strong and confined to
the nucleus. However, no detectable changes in Rb expression
were found in the AS-1 and AS-2 cells (Figure 4, panels A3 and
A4 respectively) as compared to the parental cells, and vector-
transfected cells (Figure 4, panels A1 and A2 respectively).
Similarly for another tumour suppressor protein p16INK4a which
is known to regulate cell cycle progression and arrests cells by
inhibiting the activity of cdk. However, the staining of p16 in these
cells was found to be very weak or negative in all of the four
clones (Figure 4, row B).
For the H-rasproto-oncogene (Figure 4, row C), no gross alter-
ations in the expression of p21-H-rasprotein were found in the
four different clones, and most of the cells showed negative or
weak staining in the cytoplasm.
DISCUSSION
In this study, a glioblastoma cell line U87MG that was previously
shown to have over-expressed EGFR and with wild-type p53, was
transfected with the antisense-EGFR constructs. The stable trans-
fectants were found to be suppressed in cell growth, increased in
G1 arrest and decreased in Ki-67 staining (Tian et al, 1998) which
are in accordance with the notion that enhanced expression of
EGFR are, at least in part, responsible for the aggressive cell
growth associated with the tumour cells. This is the first report
showing that the enhanced expressions of the nuclear suppressors1000 XX Tian et al
British Journal of Cancer (1999) 81(6), 994–1001 © 1999 Cancer Research Campaign
p53 and PML were associated with the increased G1 cells in the
antisense-EGFR transfectants. These results are also in keeping
with the role of PML and p53 as growth suppressors and cell cycle
G1 regulators. Increased expression of PML and wild-type p53
protein has been shown to be associated with G1 arrest and inhibi-
tion of cell growth (Mu et al, 1994; Chan et al, 1998). It may
indicate that p53 and PML are in the EGFR mitogen-activation
cascade and they are the downstream targets of EGFR. However,
the expressions of other G1 phase regulatory proteins including
cdk4, Rb and p16INK4a, as well as the proto-oncoprotein H-ras were
not altered in the antisense-EGFR clones. Thus, the altered expres-
sions of p53 and PML in the blocked EGFR pathway appear to be
specific in these glioma cells. Moreover, there are reports on the
nuclear localization of EGFR (Cao et al, 1995; Bandyopadhyay
et al, 1998) which raise the possibility that EFGR might regulate
PML or p53 directly.
However, a report on the elevation of EGFR leading to
increased resistance to cisplatin induced cytotoxicity had been
documented (Dickstein et al, 1995). In addition, by blocking
EGFR with anti-EGFR antibody, cells were found to be more
sensitive to cisplatin treatment (Mendelsohn and Fan, 1997). We
have analysed apoptosis induced by cisplatin in U87MG cells with
the TUNEL assay. Preliminary data revealed that 12~15% of the
cells were positive in AS-1 and AS-2 respectively, while only
7~9% were found in the parental and empty vector-transfected
cells (Tian et al, unpublished data). These results apparently are in
keeping with the role of p53 and PML as apoptosis regulators
(Gomez-Manzano et al, 1997; Hess and Korsmeyer, 1998).
However, the antisense-RNA of EGFR was found to block
cisplatin-induced programmed cell death in a human breast cancer
cell line MDA-468 in one report which differed from ours and
others (Dixit et al, 1997). The reason for this discrepancy is
currently unknown, but the differential molecular profiles of
individual cell lines may account for the differential effect
(Mendelsohn and Fan, 1997). For example, MDA-468 contains
mutated p53 and the Rb gene is deleted (Mendelson and Fan,
1997), while our cell line U87MG contains wild-type p53 and the
Rb gene (Gomez-Manzano et al, 1997).
On the other hand, the PML expression was found to convert
from the nuclear dot pattern into patched-like pattern or as fine-
granulated homogeneous staining pattern in cells treated with the
antisense-EGFR. Enhanced PML protein was associated with
inflammation, and altered expression was found during the onco-
genesis of many types of cancers (Koken et al, 1995; Terris et al,
1995). We have previously shown that the optimal expression of
PML in the POD structure is at G1 arrest (Chan et al, 1997). PML
co-localized with proteins including Sp-100, NDP55, PIC 1, Int-6,
and SUMO in the POD structure (Lamond and Earnshaw, 1998),
and may play a role in viral infection and replication (Everett and
Maul, 1994; Puvion-Dutilleul et al, 1995). One hypothesis put
forth (Maul et al, 1995) is that the nuclear bodies or POD may
represent storage sites of certain matrix proteins readily accessible
throughout the chromatin in response to stress or other effectors
that induce global nuclear changes. Thus, PML may act as a
matchmaker to recruit or sequester other proteins in or out of the
POD. The redistribution of PML from a few dotted structures to
granular staining pattern in antisense-EGFR cells may represent
global rearrangements of nuclear proteins.
The relationship of EGFR and p53 in brain tumours has been
reported previously which includes a report on the immunohisto-
chemical staining of astrocytomas (Kordek et al, 1995). A small
percentage of samples (9%) was stained double-positive for p53
and EGFR. However, these cases did not show any difference in
survival rate nor in the tumour grades. Since the enhanced expres-
sion of p53 may indicate the presence of a mutated protein or
increased expression of normal protein, the significance of these
findings is not known. Another report showed that p53 could
activate the trk tyrosine kinase by hyper-phosphorylation, but had
no effect on EGFR (Montano, 1997), while EGFR can be activated
by p53 through the binding to a p53 response element at the EGFR
promoter (Ded et al, 1994; Ludes-Meyers et al, 1996). Our data
provide strong evidence for the reverse pathway of EGFR in
regulating p53, indicating that the interaction of these molecules
were linked. On the other hand, another report (Vallian et al, 1997)
suggested that PML, as a transcriptional regulator, might repress
the transcriptional activity of the EGFR promoter also. Thus, the
regulation of membrane signals and nuclear events appears to be
quite complex (Tang et al, 1997). Nevertheless, the autocrine loop
of TGF-a and EGF/EGFR plays a dominant role in the aberrant
cell growth of many types of tumours including glioblastomas.
The elucidation of the molecular details of this signal transduction
pathway especially the nuclear events is, therefore, crucial in
developing effective therapeutic strategy for these tumors.
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